Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the ...
CRC heads into 2026 with a steadier base: disciplined capex, stronger liquidity, and visible CCS milestones supported by improving California policy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback